Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cresco Labs Inc. (CRLBF)
USD0.78
0.00 (-0.45%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
600 W. Fulton Street 60661
Chicago, IL, US
Chicago, IL, US
CEO
Charles Bachtell
Website
crescolabs.com
IPO
2018-12-03
CIK 1832928 ISIN CA22587M1068
Also trades on
Canadian Securities Exchange · CL.CN (CAD)
Other OTC · CRLBF (USD)
Description
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.78
0.00 (-0.45%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
747.7K
Beta
1.71
Float Shares
335.33M
Free Float %
97.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.17% | -6.76% | +8.55% | +3.78% | -13.19% | -18.13% | +38.38% | -31.96% | -91.52% | -79.70% | -79.70% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
0.78
Low
2.50
+220.7%
Consensus
5.50
+605.5%
Median
5.50
+605.5%
High
8.50
+990.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
5.50
+605.5%
|
Quality scores
Altman Z-Score
-0.72
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-7.9% Q1'26: -10.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-90.9% Q1'26: +13.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.5% Q1'26: -8.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+11.8% Q1'26: +9.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.5% ★ Q1'26: +7.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.4% ★ Q1'26: +4.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.55× Q1'26: 5.16× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.31M
est: 42.58M (-75.8%)
|
43.25M
est: 42.58M (+1.6%)
|
128.53M
est: 138.53M (-7.2%)
|
476.25M
est: 475.57M (+0.1%)
|
821.68M
est: 837.80M (-1.9%)
|
842.68M
est: 846.12M (-0.4%)
|
770.89M
est: 764.33M (+0.9%)
|
724.34M
est: 721.79M (+0.4%)
|
667.33M
est: 655.33M (+1.8%)
|
634.26M
622.32M – 643.00M
-3.2% YoY
|
677.57M
658.21M – 707.52M
+6.8% YoY
|
686.15M
668.59M – 702.54M
+1.3% YoY
|
689.10M
671.47M – 705.56M
+0.4% YoY
|
706.10M
688.03M – 722.97M
+2.5% YoY
|
| EBITDA |
-3.48M
est: -520.0K (-569.6%)
|
9.66M
est: -520.0K (+1,958.2%)
|
-29.47M
est: -1.69M (-1,642.1%)
|
5.23M
est: -5.81M (+190.0%)
|
-157.04M
est: -10.23M (-1,434.8%)
|
-10.24M
est: -10.33M (+0.9%)
|
-14.62M
est: -9.33M (-56.6%)
|
108.79M
est: 17.30M (+529.0%)
|
128.03M
est: 15.70M (+715.3%)
|
15.20M
14.91M – 15.41M
-3.2% YoY
|
16.24M
15.77M – 16.95M
+6.8% YoY
|
16.44M
16.02M – 16.83M
+1.3% YoY
|
16.51M
16.09M – 16.91M
+0.4% YoY
|
16.92M
16.49M – 17.32M
+2.5% YoY
|
| EBIT |
-44.0K
est: -3.70M (+98.8%)
|
7.49M
est: -3.70M (+302.3%)
|
-42.28M
est: -12.05M (-250.9%)
|
-31.53M
est: -41.36M (+23.8%)
|
-201.59M
est: -72.87M (-176.6%)
|
-65.68M
est: -73.59M (+10.8%)
|
-85.19M
est: -66.48M (-28.2%)
|
45.97M
est: -36.25M (+226.8%)
|
78.46M
est: -32.91M (+338.4%)
|
-31.85M
-32.29M – -31.25M
+3.2% YoY
|
-34.03M
-35.53M – -33.06M
-6.8% YoY
|
-34.46M
-35.28M – -33.58M
-1.3% YoY
|
-34.61M
-35.43M – -33.72M
-0.4% YoY
|
-35.46M
-36.31M – -34.55M
-2.5% YoY
|
| Net Income |
-85.8K
est: 7.47M (-101.1%)
|
-1.92M
est: 7.47M (-125.6%)
|
-43.20M
est: -40.93M (-5.5%)
|
-102.16M
est: -16.73M (-510.6%)
|
-319.60M
est: -272.23M (-17.4%)
|
-212.05M
est: -32.65M (-549.4%)
|
-175.52M
est: -177.27M (+1.0%)
|
-74.44M
est: -66.14M (-12.5%)
|
-142.50M
est: -50.83M (-180.4%)
|
-22.70M
-39.73M – -11.35M
+55.3% YoY
|
-7.49M
-7.72M – -7.24M
+67.0% YoY
|
8.51M
8.23M – 8.78M
+213.6% YoY
|
-10.21M
-10.53M – -9.88M
-220.0% YoY
|
3.40M
3.29M – 3.51M
+133.3% YoY
|
| SGA |
44.4K
est: 15.82M (-99.7%)
|
31.21M
est: 15.82M (+97.3%)
|
91.52M
est: 51.47M (+77.8%)
|
179.97M
est: 176.70M (+1.9%)
|
317.80M
est: 311.28M (+2.1%)
|
350.65M
est: 314.37M (+11.5%)
|
274.63M
est: 283.98M (-3.3%)
|
232.27M
est: 263.65M (-11.9%)
|
231.25M
est: 239.37M (-3.4%)
|
231.68M
227.31M – 234.87M
-3.2% YoY
|
247.49M
240.42M – 258.44M
+6.8% YoY
|
250.63M
244.22M – 256.62M
+1.3% YoY
|
251.71M
245.27M – 257.72M
+0.4% YoY
|
257.92M
251.32M – 264.08M
+2.5% YoY
|
| EPS |
-2.63
est: 0.02 (-12,259.6%)
|
-0.03
est: 0.02 (-249.3%)
|
-0.37
est: -0.12 (-212.3%)
|
-0.49
est: -0.05 (-911.7%)
|
-1.22
est: -0.79 (-54.8%)
|
-0.71
est: -0.09 (-651.2%)
|
-0.54
est: -0.51 (-5.2%)
|
-0.22
est: -0.19 (-13.3%)
|
-0.42
est: -0.15 (-181.4%)
|
-0.07
-0.12 – -0.03
+55.3% YoY
|
-0.02
-0.02 – -0.02
+67.0% YoY
|
0.03
0.02 – 0.03
+213.6% YoY
|
-0.03
-0.03 – -0.03
-220.0% YoY
|
0.01
0.01 – 0.01
+133.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-37.67M
OE per share TTM
-0.10
Owner's Yield
-9.94%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
61.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
88.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
2
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nomura Global Financial Products, Inc. | 24.30M | 7.60% | — | 24.30M | — | 24.30M | BD | Japan | 2024-02-14 | ↗ |
| 2 | Nomura Holdings, Inc. | 24.30M | 7.60% | — | 24.30M | — | 24.30M | HC | Japan | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-3 vs prev Q
New positions
2
Closed positions
5
Increased
3
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FIRST NATIONAL TRUST CO | 113.8K +— (+0.0%) | 99.0K -41.0K (-29.3%) | 0.03% +0.002 pp | 0.00% -0.001 pp | USD0.91 -2.2% | 6 qtrs — |
| 2 | ALBERT D MASON INC | 88.0K -3.1K (-3.4%) | 76.6K -35.5K (-31.7%) | 0.03% +0.000 pp | 0.05% -0.024 pp | USD7.04 -87.4% | 27 qtrs — |
| 3 | HANTZ FINANCIAL SERVICES, INC. | 9.0K +10.0 (+0.1%) | 8.0K -3.0K (-27.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.66 -86.6% | 18 qtrs — |
| 4 | STRATEGIC INVESTMENT SOLUTIONS, INC. /IL | 1.4K +— (+0.0%) | 1.2K -507.0 (-29.3%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD1.26 -29.4% | 8 qtrs — |
| 5 | GOLDEN STATE EQUITY PARTNERS | 1.3K +1.3K (+100.0%) | 1.1K +1.1K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.89 +0.0% | 1 qtrs NEW |
| 6 | HURLEY CAPITAL, LLC | 1.0K +1.0K (+100.0%) | 882.00 +882.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD0.89 +0.0% | 6 qtrs — |
| 7 | THOMPSON INVESTMENT MANAGEMENT, INC. | 725.00 +— (+0.0%) | 631.00 -261.0 (-29.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.55 -42.6% | 13 qtrs — |
| 8 | MASSMUTUAL TRUST CO FSB/ADV | 200.00 +— (+0.0%) | 174.00 -72.0 (-29.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.55 -42.6% | 28 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Pure US Cannabis ETF MSOS | 2.64% | 24.18M | 0.81% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
27.8K
Shares Outstanding
343.23M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Charles Bachtell | Co-Founder, Chief Executive Officer & Director | 1M | male |
| Gregory Butler | President | 807.0K | male |
| Sharon Schuler | Chief Financial Officer | 141.7K | female |
| Robert Sampson | Co-Founder & Independent Director | 76.6K | male |
| Ty Gent | Chief Operating Officer | — | male |
| Angie Demchenko | Chief People Officer | — | female |
| Zach Marburger | Chief Information Officer | — | male |
| Cole | Senior Vice President of Corporate Development and Investor Relations | — | — |
| John Schetz | General Counsel | — | male |
| Joseph Ales | Senior Vice President of Operations | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRLBF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
